He has an extensive track record in sourcing, evaluating, and scaling biotech and pharma companies, and has successfully led multiple investment rounds on behalf of investment funds and family offices.

Throughout his career, Paul has played a pivotal role in building and guiding early-stage companies from scientific concept through key clinical and commercial milestones, combining deep technical insight with disciplined capital allocation and value creation.

At Meneldor, Paul has co-led investments in Xenikos, Atriva Therapeutics, The Aptamer Group, LightOx, Tagworks Pharmaceuticals, Hemispherian, TIBEAY BioSciences, and Mithrilium Therapeutics, contributing to portfolio construction, transaction structuring, and hands-on company development.

Since 1992, he has been one of the founding partners of the Synthon group of companies and a key driver of its growth, helping to scale the organisation to more than 1,500 employees across nine global locations. Frans played a central role in the development, regulatory strategy, manufacturing, and commercialisation of generic medicines, biosimilars, and novel biological entities.

His deep operational, regulatory, and scientific expertise enables him to identify high-potential technologies early and to guide companies through the complexity of pharmaceutical development, from discovery through approval and market entry.

She has led complex, cross-border initiatives spanning corporate and commercial strategy, go-to-market and portfolio choices, M&A integration, and operating-model redesign in global environments.
Throughout her career, Margrit has worked at the intersection of strategy and execution—helping organisations define where to play and how to win, professionalise and scale internationally, and translate innovation into sustainable commercial outcomes. She is known for building high-performing leadership teams, aligning diverse stakeholders, and converting strategic priorities into measurable results.
At Meneldor, Margrit supports portfolio companies and co-investments in shaping strategic direction, strengthening governance, and preparing for critical funding, partnership, and scaling milestones.
Margrit is a member of the Investment Committee of the Brabantse Ontwikkelings Maatschappij (BOM) and serves as a board member of Diamid, a healthcare and diagnostics foundation.

He brings deep, long-standing experience across the full drug development, manufacturing, and quality value chain.

He spent more than 20 years at Synthon in various R&D leadership roles, primarily in R&D Project Management and in managing product and process transfers to Contract Manufacturing Organizations.

Today, Cees plays a pivotal role in Meneldor’s new biopharma ventures, where he leads CMC strategy and execution. His extensive operational expertise and pragmatic leadership are instrumental in advancing these programs toward clinical readiness.